NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) to Harmony Biosciences Holdings, Inc. is fair to Zynerba shareholders. Under the terms of the agreement, Harmony would acquire all outstanding shares of Zynerba for $1.1059 per share in cash, plus one non-tradeable contingent value right per share, representing the right to receive potential additional payments of up to $140 million in the aggregate, subject to the achievement of certain clinical, regulatory and sales milestones.
Halper Sadeh encourages Zynerba shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
The investigation concerns whether Zynerba and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Zynerba shareholders; (2) determine whether Harmony is underpaying for Zynerba; and (3) disclose all material information necessary for Zynerba shareholders to adequately assess and value the merger consideration. On behalf of Zynerba shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh encourages Zynerba shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
